Wolverine Legal Status, FDA 503A Category, and Compounding Access

The present-tense regulatory facts

Both peptides in the Wolverine legal status picture are, today, FDA 503A Category 2 bulk drug substances. FDA identified BPC-157, and separately "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," as bulk drug substances that may present significant safety risks, and placed both in Category 2 for 503A compounding effective with the September 29, 2023 update to its nominated-substances list ^[13]. Neither is an FDA-approved drug, and the blend has no approved therapeutic indication ^[13].

Category 2 has a specific meaning. Per FDA's interim policy, Category 2 substances are those nominated with enough information for FDA to evaluate but which FDA has identified as raising significant safety risks — and they are not covered by the enforcement-discretion policy that applies to Category 1 ^[14]. FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[14]. For these two peptides, FDA's stated concerns include potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization ^[13].

This is the costume the rest of the site is built around: a regulatory ledger read first, with the research record kept honest against it. The deeper research findings for BPC-157 and TB-500 describe what the constituents do in animals; this page describes where they stand with FDA.

Access under active review — and what that does not mean

The access picture for this class of peptides is under active FDA evaluation, and it may change. Both BPC-157 ("BPC-157 (free base)" / "BPC-157 acetate") and TB-500 ("TB-500 (free base)" / "TB-500 acetate") appear on the published agenda of the Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, as substances "being considered for inclusion on the 503A Bulks List" ^[15].

That is a scheduled evaluation and discussion — not a listing decision, not a reclassification, and not a change in current status ^[15]. A PCAC discussion is advisory; inclusion on a final bulks list is decided by FDA rulemaking informed by, but not determined by, the committee ^[14]. No outcome of the July 2026 meeting should be assumed or dated. As of now, the confirmable FDA position on both peptides is Category 2 ^[13].

The honest forward-looking statement is therefore narrow: access for this class is being actively reviewed and could expand depending on FDA action, with the next scheduled step a discussion in 2026. Anything beyond that — a specific reclassification, a date, a "removed from Category 2" claim — is not established by an authoritative FDA source and is not stated here.

How compounded access works for this class of substance

Compounding in the United States is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight ^[14].

In general terms, a legally compounded medication is prepared only after a licensed prescriber evaluates an individual patient — in person or through a compliant telehealth encounter — determines a compounded preparation is appropriate, and issues a valid, patient-specific prescription ^[14]. The preparation is then made by a state-licensed 503A pharmacy or sourced from a 503B outsourcing facility. Telehealth is one front-end channel for that prescriber evaluation; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription ^[14].

There is one binding caveat for this class. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or is on FDA's 503A bulks list ^[14]. Substances FDA has flagged for significant safety risks — which is where BPC-157 and TB-500 currently sit — are not eligible for routine 503A compounding while that status stands ^[13]. This page describes the general regulatory landscape, not a way to obtain any substance; it names no pharmacy, clinic, or telehealth provider, and it is general information, not medical or legal advice.

WADA status

In sport, both constituents are prohibited. BPC-157 falls under the World Anti-Doping Agency's S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 falls under prohibited peptide and growth-factor categories ^[7]. The blend is banned for the relevant classes in and out of competition ^[7]. This is a separate matter from the FDA compounding status, but it is part of the same honest reading: neither leg of the BPC-157 TB-500 blend is an approved medicine, and both are barred in regulated sport ^[7].

Regulatory questions

What is the FDA 503A status of the Wolverine blend?

Both constituents are FDA 503A Category 2 bulk drug substances, effective with FDA's September 29, 2023 update ^[13]. Category 2 means FDA identified significant safety risks and that the substance is not covered by the enforcement-discretion policy applying to Category 1 ^[14]. The blend itself has no separate status — each peptide is evaluated individually ^[13].

Can you get BPC-157 from a compounding pharmacy?

BPC-157 is currently an FDA 503A Category 2 substance, which is not eligible for routine 503A pharmacy compounding while that status stands ^[13]. In general, lawful compounding requires a licensed-prescriber evaluation and a valid, patient-specific prescription, and the active ingredient must be eligible under the 503A/503B bulk-substance rules ^[14]. This page names no pharmacy or provider and offers general information, not access guidance.

Is the Wolverine (BPC-157 + TB-500) blend legal?

Neither BPC-157 nor TB-500 is an FDA-approved drug, and the blend has no approved indication ^[13]. Both are FDA 503A Category 2 substances as of September 29, 2023 — flagged for significant safety risks and outside the Category 1 enforcement-discretion policy ^[13][14] — and both are prohibited by WADA in sport ^[7]. This is a description of regulatory status, not legal advice.

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and the blend has no approved indication ^[13]. Both are prohibited by WADA: BPC-157 under the S0 non-approved-substances category and TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories ^[7].